Compare Johnson & Johnson (JNJ) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Symbotic Inc — how do they compare? Johnson & Johnson trades at $260.84 (market cap $626.09B), while Symbotic Inc trades at $41.2 (market cap $5.41B). The key difference: Johnson & Johnson is far larger — about 115.7× Symbotic Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| JNJ | SYM | |
|---|---|---|
Market Cap | $626.09B | $5.41B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $87.30 |
52-Week Low | $172.78 | $38.57 |
Enterprise Value | $654.37B | $3.67B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
SYM trades at $41.17, up 2.64% today but facing bearish technical signals with 15 sell indicators. The company reported mixed Q3 2026 results with revenue growth of 21.7% but an earnings miss. Despite negative net income of -$16.94M in 2025, cash flow remains strong at $516.84M and analysts maintain a $60 consensus target with 61% buy ratings.
SYM presents a growth story with expanding revenue and margin improvements, but faces execution risks amid recent earnings misses. The stock offers potential upside to analyst targets but requires careful monitoring of profitability trends and competitive pressures in the warehouse automation sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
